Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCGS 20625 is a selective, partial agonist for the benzodiazepine binding site of the GABAA receptor. Potently inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors (IC50 = 1.3 nM) and displays weak affinity for peripheral benzodiazepine (IC50 = 0.68 - 2.25 μM) and GABA binding sites (IC50 > 10000 μM). Displays anxiolytic activity in vivo following oral administration..
分子量 | 309.36 |
公式 | C18H19N3O2 |
储存 | Store at +4°C |
纯度 | ≥99% (HPLC) |
CAS Number | 111205-55-1 |
PubChem ID | 163844 |
InChI Key | UBLXQFIFWUEVGJ-UHFFFAOYSA-N |
Smiles | COC1=CC=C(C=C1)N1N=C2C(=CNC3=C2CCCCC3)C1=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Bennett (1987) Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions. Physiol.Behav. 41 241 PMID: 2893398
Williams et al (1989) CGS 20625, a novel pyrazolopyridine anxiolytic. J.Pharmacol.Exp.Ther. 248 89 PMID: 2563294
Jarvis et al (1990) CGS 20625, a novel pyrazolopyridine with selective anxiolytic activity. Prog.Clin.Biol.Res. 361 477 PMID: 1981266
关键词: CGS 20625, CGS 20625 supplier, Selective, central, benzodiazepine, receptor, partial, agonists, GABAA, Receptors, CGS20625, 2467, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CGS 20625 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.